high5immunology.tv | IBD | UEG Week 2022

Therapeutic concepts: Discussions

UEGweek 2022

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro, S. Danese

What is new in anti-TNFα therapy?

VEGA, REACT-2

UEGweek 2022

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

Treat-to-target with ustekinumab - why didn't it work?

STARDUST

UEGweek 2022

A. Dignass, M. Allez, A. Armuzzi, M. Fantini

Personalized therapy - de-escalation strategies

LADI

UEGweek 2022

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

The benefit of early intervention in CD

LOVE-CD

UEGweek 2022

S. Schreiber, A. Dignass, M. Allez, A. Armuzzi, D. Laharie, M. Fantini

Is IL-23 the super target?

UEGweek 2022

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

What is the best dose of adalimumab in CD?

LADI

UEGweek 2022

S. Schreiber, A. Dignass, M. Allez, A. Armuzzi, D. Laharie, M. Fantini

Treat-to-target still alive?

REACT-2

Therapeutic concepts ENG

UEGweek 2022

Gerhard Rogler, MD

Postoperative monitoring matters!

UEGweek 2022

Matthieu Allez, MD

Longterm potential benefit of a combIo therapy

VEGA

UEGweek 2022

Gerhard Rogler, MD

Thinking out of the box - co-medication of the elderly

UEGweek 2022

Fernando Magro, MD

Pharmacokinetics of ustekinumab in the STARDUST trial

STARDUST

UEGweek 2022

Piotr Eder, MD

T reg - a new therapeutic target in IBD?

UEGweek 2022

Massimo Fantini, MD

Treat-to-target strategy is superior to conventional...

REACT-2

UEGweek 2022

Gerassimos Mantzaris

You can still treat severe biofailure in CD

UEGweek 2022

Silvio Danese, MD

Small molecules in crohn's disease

UEGweek 2022

David Laharie, MD

VEGA - the story continues

VEGA

UEGweek 2022

Stefan Schreiber, MD

TYK2 Deucravacitinib in ulcerative colitis

LATTICE-UC

UEGweek 2022

James Lindsay, MD

Enhanced treatment algorithm for the management of CD

REACT-2

UEGweek 2022

Gerassimos Mantzaris

Once more a shocking message: be aware of steroids!

LOVE-CD

UEGweek 2022

Fernando Gomollon, MD

Explosion of new drugs

UEGweek 2022

Piotr Eder, MD

Oral anti-integrin therapy in IBD - new data, new...

IDEAL

UEGweek 2022

Massimo Fantini, MD

Combination therapy: week 38 efficacy and safety data...

VEGA

UEGweek 2022

Iris Dotan, MD

Treating the patient as a whole

UEGweek 2022

Matthieu Allez, MD

Anti-IL-23 monoclonal antibodies: is it better to...

UEGweek 2022

Gerassimos Mantzaris, MD

No matter what you use - treat early!

Therapeutic concepts Multi Language

UEGweek 2022

David Laharie, MD

VEGA - l'histoire continue

VEGA

UEGweek 2022

Stefan Schreiber, MD

TYK2 Deucravacitinib bei Colitis ulcerosa

LATTICE-UC

UEGweek 2022

Piotr Eder, MD

Doustna terapia antyintegrynowa - nowe dane, nowe...

IDEAL

UEGweek 2022

Gerassimos Mantzaris, MD

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα...

LOVE-CD

UEGweek 2022

Matthieu Allez, MD

Les résultats à long terme d'une combIothérapie

VEGA

UEGweek 2022

Massimo Fantini, MD

Terapia di combinazione: efficacia e sicurezza a 38...

VEGA

UEGweek 2022

Fernando Gomollon, MD

Explosión de nuevos fármacos

UEGweek 2022

Gerhard Rogler, MD

Was tun nach der Operation?

UEGweek 2022

Gerassimos Mantzaris

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

UEGweek 2022

Iris Dotan, MD

Treating the patient as a whole

UEGweek 2022

Gerhard Rogler, MD

Thinking out of the box - Einfluss der...

UEGweek 2022

Massimo Fantini, MD

Una strategia “Treat-to-target” è superiore rispetto...

REACT-2

UEGweek 2022

Piotr Eder, MD

T reg - nowy cel terapeutyczny w IBD?

UEGweek 2022

Matthieu Allez

Anticorps anti-IL-23: est-il préferabble de cibler...

UEGweek 2022

Gerassimos Mantzaris, MD

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά...

UEGweek 2022

Silvio Danese, MD

Small molecules nel morbo di crohn

Targeting efficacy: Discussions

UEGweek 2022

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro, S. Danese

1st JAK inhibitor in CD - a game changer?

U-EXCEL

UEGweek 2022

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro, S. Danese

Update on JAK inhibition in UC

U-ACHIEVE

UEGweek 2022

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro

S1P receptor modulators

ELEVATE UC 52, ELEVATE UC 12, TRUE NORTH

UEGweek 2022

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro

Update on IL-23 inhibition in UC

LUCENT-1, LUCENT-2

Targeting efficacy ENG

UEGweek 2022

Peter Irving, MD

Ozanimod works in young and old UC patient

TRUE NORTH

UEGweek 2022

Massimo Fantini, MD

Final efficacy and safety results from Upadacitinib 52...

U‑ACHIEVE

UEGweek 2022

David Laharie, MD

Risankizumab in refractory CD patients

UEGweek 2022

Silvio Danese, MD

VEGA & LUCENT studies

VEGA, LUCENT-1, LUCENT-2

UEGweek 2022

Stefan Schreiber, MD

Upadacitinib - induction therapy in CD

U-EXCEL

UEGweek 2022

James Lindsay, MD

Estrasimod in moderate to severe active UC

ELEVATE UC 52 & 12

UEGweek 2022

Iris Dotan, MD

The era of small molecules

UEGweek 2022

Massimo Fantini, MD

Persistance on therapy and real-world clinical...

UEGweek 2022

Axel Dignass, MD

Selective IL-23 blockade

QUASAR, LUCENT-1, LUCENT-2, FORTIFY

UEGweek 2022

Peter Irving, MD

Upadacitinib maintenance therapy - final results from...

U-ACHIEVE

UEGweek 2022

James Lindsay, MD

The 1st JAKi in CD

U-EXCEL

UEGweek 2022

Fernando Magro, MD

Histological response and remission induced by...

LUCENT-1, LUCENT-2

UEGweek 2022

Axel Dignass, MD

JAK-inhibition

U-ACHIEVE

Targeting efficacy Multi Language

UEGweek 2022

Axel Dignass, MD

Selective IL-23 Blockade

QUASAR, LUCENT-1, LUCENT-2, FORTIFY

UEGweek 2022

Iris Dotan, MD

The area of small molecules

UEGweek 2022

Axel Dignass, MD

JAK-Inhibition

U-ACHIEVE

UEGweek 2022

Massimo Fantini, MD

Risultati finali di efficacia e sicurezza a 52...

U‑ACHIEVE

UEGweek 2022

David Laharie, MD

Risankizumab dans la maladie de Crohn réfractaire

UEGweek 2022

Silvio Danese, MD

VEGA & LUCENT studi clinici

VEGA, LUCENT-1, LUCENT-2

UEGweek 2022

Stefan Schreiber, MD

Upadacitinib - Induktionsdaten bei CD

U-EXCEL

UEGweek 2022

Massimo Fantini, MD

Persistenza in terapia ed efficaci clinica di...

Targeting safety: Discussions

UEGweek 2022

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

Treating the elderly - closer surveillance and the...

UEGweek 2022

A. Dignass, M. Allez, A. Armuzzi, M. Fantini

Updated safety data on JAK inhibitors

OCTAVE

Treatment Goals: Discussions

UEGweek 2022

A. Schreiber, A. Dignass, M. Allez, A. Armuzzi, D. Laharie, M. Fantini

Steroid effects as treatment goals: quality of life and...

UK IBD BioResource database

UEGweek 2022

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

Urgency - putting the focus on an important endpoint!

U-ACHIEVE/U-ACCOMPLISH, LUCENT, CONFIDE

Treatment Goals ENG

UEGweek 2022

Axel Dignass, MD

New endpoints in IBD

CONFIDE

UEGweek 2022

Fernando Magro, MD

Filgotinib is efficacious in inducing and maintaining...

SELECTION

UEGweek 2022

Axel Dignass, MD

Patient reported outcomes in IBD

UEGweek 2022

Peter Irving, MD

Urgency matters!

LUCENT-1, LUCENT-2

Treatment Goals Multi Language

UEGweek 2022

Axel Dignass, MD

Patienten gerichtete Endpunkte bei CED

UEGweek 2022

Axel Dignass, MD

Neue Studienendpunkte in IBD

CONFIDE

Diagnostics and Prediction ENG

UEGweek 2022

Stefan Schreiber, MD

Whats's the origin of Crohn's genetics ? The history of...

UEGweek 2022

Fernando Gomollon, MD

Explosion of Spanish contributions

SEXEII, BUTTERFLY

Diagnostics and Prediction Multi Language

UEGweek 2022

Fernando Gomollon, MD

Explosión de las comunicaciones españolas

UEGweek 2022

Stefan Schreiber, MD

Wo kommt die Crohn-Genetik her? Die Historie der IL-23...

Varia ENG

UEGweek 2022

Axel Dignass, MD

Personalised therapy in IBD

LADI, LUCENT-1, LUCENT-2

Varia Multi Language

UEGweek 2022

Axel Dignass, MD

Individualisierte Therapie bei CED

LADI, LUCENT-1, LUCENT-2